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Background: Vitiligo is a common pigmentary skin disorder, aﬀecting 0.5–1% of world population. It is one of the psychologically
devastating skin disorders, which have diﬀerent medical and surgical modalities of treatment.
Objective: To report the failure of non-cultured melanocyte–keratinocyte transplantation in periungual vitiligo.
Method: The method used was introduced by Gauthier and Surleve-Bazeille, modiﬁed by Olsson and Juhlin, and recently by
Mulekar. A shaved biopsy skin sample of approximately one-ﬁfth the size of the recipient area was used. Skin sample is incubated; cells
mechanically separated using trypsin-EDTA solution, and then centrifuged to prepare a suspension. The suspension is then applied to
dermabraded depigmented skin area and collagen dressing was used to keep it in place.
Results: Treated lesions on the right hand of female with stable periungual vitiligo showed very poor repigmentation (less than 10%)
with only very small new brown spots.
Conclusion: Acral vitiligo is one of the diﬃcult-to-treat areas, and further studies are required to explain the variable outcomes of
non-cultured melanocyte–keratinocyte transplantation treatment of clinically stable acral vitiligo patients.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Vitiligo is a common pigmentary skin disorder,
characterized by total or partial loss of melanocytes from
the epidermis and other tissues. It aﬀects 0.5–1% of world
population (Kanika et al., 2011). This dermatological
problem is one of the most psychologically devastatinghttp://dx.doi.org/10.1016/j.jdds.2014.10.002
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Peer review under responsibility of King Saud University.and diﬃcult to treat skin diseases (Pearl, 2005). Currently,
diﬀerent medical therapies for vitiligo are available,
including topical and systemic corticosteroids, topical
Calcineurin inhibitors, and phototherapy (Kanika et al.,
2011). However, medical therapies fail to repigment lesions
on the glabrous skin and rarely lead to complete repig-
mentation (El Zawahry et al., 2011). For such instances,
and for patients in whom vitiligo has been stable, various
surgical therapies have been used for the last 25 years
(Pearl, 2005). Surgical techniques may be divided into
two types: tissue grafting methods such as split-thickness
skin graft, punch grafting and suction-blister roof grafting,
and cellular grafting methods that include non-cultured
keratinocytes/melanocytes and cultured melanocytes
(Richard et al., 2011).ehalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
Figure 1. The right hand, pre-transplantation.
Figure 2. 25 days post transplantation, the right hand showing <10%
repigmentation.
124 N. Alsubait et al. / Journal of Dermatology & Dermatologic Surgery 19 (2015) 123–125Vitiligo may aﬀect any site of the body, but aﬀects
mainly those sites which are exposed to trauma and pres-
sure such as knees, elbows, and ﬁngers (David Njoo and
Wiete, 2001). Hands and ﬁngers are known to be diﬃ-
cult-to-treat sites (Rafal et al., 2007). Here, we report a
case of periungual vitiligo, treated with autologous non-
cultured melanocyte-keratinocyte cell transplantation, at
the National Center for Vitiligo and Psoriasis (NCVP),
Riyadh, Saudi Arabia.
A shaved biopsy skin sample of approximately one-ﬁfth
the size of the recipient area (right hand) was obtained
from the donor area (upper lateral aspect of the thigh)
using standard aseptic precautions. The donor area was
dressed with 4  4 DuoDerm and sterile gauge that was
cleaned and removed after one week. The skin sample
was transferred to a Petri dish containing 0.2% (weight/vol-
ume) trypsin solution and incubated for 40 min at 37 C.
After 40 min of incubation, trypsin was removed with a
Pasteur pipette, and the skin sample was taken out for
separation. It was washed with Dulbecco’s Modiﬁed Eagle
Medium/F12 (DMEM/F12 medium Life Technologies,
Carlsbad, CA, USA), to remove residual trypsin. The der-
mis was separated from the epidermis mechanically and
discarded. The epidermis in the Petri dish was broken
down to multiple small pieces and then centrifuged for
5 min, to facilitate the preparation of cell suspension. The
ﬂoating epidermal pieces were discarded, and the cell sus-
pension – prepared in DMEM/F12 medium using a 1 ml
syringe with a detachable needle. The recipient area was
anesthetized using 1% Xylocaine, and dermabraded with
a diamond fraise wheel. The cell suspension was applied
to the recipient area, and wound was covered directly with
dry, thin collagen sheet, that was subsequently covered
with sterile gauze pieces moistened with DMEM/F12.
The dressing was removed after one week. The Ethics
Committee of the National Center for Vitiligo and Psoria-
sis approved the treatment.
2. Case report
A 33-year-old married, housewife Saudi female, known
case of hypothyroidism was ﬁrst seen in July 2003 with
depigmented lesions on her hands, neck, feet, elbows, and
upper extremities for 4 years’ duration. Her lesions had
been non progressive since the onset, and she had a nega-
tive family history of vitiligo. The patches on her right
hand measured 18.75 cm2. She failed to respond to medical
treatment. The patient underwent autologous non-cultured
melanocyte–keratinocyte cell transplantation on her right
hand in August 2003. Treated lesions on her right hand
showed very poor repigmentation (less than 10%) with only
very small new brown spots. (Figs. 1 and 2).
3. Discussion
We report periungual vitiligo treated with autologous
non-cultured melanocyte–keratinocyte transplantation,with poor response to treatment, The method which was
used in this case was introduced by Gauthier and Sur-
leve-Bazeille Gauthier and Surleve-Bazeille (1992), modi-
ﬁed by Olsson and Juhlin Olsson and Juhlin (1998) and
recently by Mulekar Mulekar (2003). It is an eﬀective pro-
cedure that takes 2–3 h and can be carried out as an outpa-
tient treatment. Also, it has excellent cosmetically accepted
outcomes, rare side eﬀects, and simpler compared with the
cultured melanocyte cell transplantation method. On the
other hand, it needs trained personnel, facilities, and dedi-
cated staﬀ.
Poor results in an acral vitiligo treated with the same
technique have been reported earlier. On reviewing the
literature, studies using this method of transplantation in
acral vitiligo showed variable results. Poor outcome was
reported using the same technique in acral areas (El
Zawahry et al., 2011; Toossi et al., 2011; Sanjeev, 2005;
Njoo et al., 1998), while others showed excellent repig-
mentation (El Zawahry et al., 2011; Sanjeev, 2004, 2005;
Sanjeev et al., 2009).
The hair follicle is considered to be the melanocyte reser-
voir (Rafael, 1997). The glabrous skin that is devoid of
these follicles such as glans penis, eyelids, and areola and
skin with sparse hair follicles as ﬁngers, toes, elbows usu-
ally are unresponsive to medical therapies due to lack of
melanocyte reservoir. Theoretically, good repigmentation
is expected in all clinically stable vitiligo lesions treated sur-
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mentation in acral lesions cannot be explained on the basis
of available evidence. Several hypotheses have been put
forward to explain the poor response in acral lesions, such
as the absence of subcutaneous tissue, technical diﬃculties.
Richard et al., Richard et al. (2011) explained that the
small percentage of excellent responders to such treatment
in such area was mostly due to the fact that they are cases
of vitiligo vulgaris with acral lesions. In our case, the
patient is a case of vitiligo vulgaris with acral lesions, and
showed less than 10% of repigmentation.
4. Conclusion
It is diﬃcult to explain the variable outcomes of non-
cultured MKTP treatment of clinically stable acral vitiligo
patients. We recommend further studies that can throw
some light to explore the underlying process and the causes
of such variability in such lesions. Finally, irrespective to
the method used, and despite the vitiliginous type, acral
lesions are considered diﬃcult areas to repigment, and
further studies are needed to see the eﬀectiveness of retreat-
ment in these patients.
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